NYSE$COR

Cencora Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Reported revenue increased by 17.7% year-over-year, with GAAP diluted EPS at $1.40 and adjusted diluted EPS at $2.16.

AmerisourceBergen Corporation reported a 17.7% increase in revenue to $53.4 billion for the third quarter of fiscal year 2021. The company's GAAP diluted EPS was $1.40, while adjusted diluted EPS increased to $2.16. The company has raised its adjusted diluted EPS guidance for fiscal year 2021 to a range of $9.15 to $9.30.

  • Revenue increased by 17.7% year-over-year to $53.4 billion.
  • GAAP diluted EPS was $1.40 for the quarter.
  • Adjusted diluted EPS increased 16.8% to $2.16.
  • Adjusted diluted EPS guidance raised to $9.15 to $9.30 for fiscal year 2021.

Headline financials

Total Revenue

$53.4B

Previous: $45.4B+17.7%
EPS (adj)

$2.16

Previous: $1.85+16.8%
Effective Tax Rate

48.5%

Previous: 16.5%+193.9%
Adj. Effective Tax Rate

21.0%

Previous: 18.8%+11.7%
Capital Expenditures

-$273M

Previous: -$251M-8.9%
Free Cash Flow

$18.7M

Previous: $38.3M-51.2%
Net Income

$292M

Previous: $289M+0.9%
Operating Income

$621M

Previous: $405M+53.3%
Gross Profit

$1.89B

Previous: $1.23B+54.0%
Cash & Equivalents

$2.55B

Previous: $3.42B-25.4%
Total Assets

$55.9B

Previous: $40.8B+37.1%
Stock-Based Comp

$14.4M

Previous: $11.8M+21.5%

Revenue & EPS history

Cencora · Revenue · Quarterly

$53.4B

Q3 2021+17.7%vs Q3 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Forward guidance

AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted average shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance Healthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the Company delivered to Walgreens at the closing of the transaction. AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company’s continued strong performance across its businesses.

Tailwinds

  • Adjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.
  • Adjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range.
  • Adjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range.
  • Pharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from growth in the high-single digit percent range.
  • Adjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.1%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+1.4%

Avg return

30 days after

48%

35 / 73 earnings

Positive

+7.8%

Q2 2019

Best reaction

-18.4%

Q2 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026-18.4%-16.6%-10.1%
Q1 2026-5.9%+0.4%-0.9%
Q4 2025+2.9%+5.8%-1.4%
Q3 2025-2.9%-0.6%+0.1%
Q2 2025+4.6%-4.3%-0.6%
Q1 2025+0.7%-2.1%+1.2%
Q4 2024+5.9%+6.5%+4.0%
Q3 2024+5.8%+4.4%+3.7%
Q2 2024-6.0%-6.3%-5.2%
Q1 2024+7.4%+6.2%+7.5%
Q4 2023+4.2%+4.7%+9.0%
Q3 2023+1.2%-1.3%-7.5%
Q2 2023+0.1%+0.7%+3.5%
Q1 2023-6.2%-8.6%-7.6%
Q4 2022+4.4%+3.1%+12.4%
Q3 2022-2.5%-1.5%+3.4%
Q2 2022+2.9%+4.4%-2.5%
Q1 2022+0.2%+1.3%+7.0%
Q4 2021-0.6%-2.8%-9.0%
Q3 2021-1.5%-2.8%+1.2%
Q2 2021-6.5%-2.1%-7.1%
Q1 2021+3.9%+1.8%-0.7%
Q4 2020-1.0%+4.8%-1.9%
Q3 2020-3.0%-1.6%-7.7%
Q2 2020+3.0%+3.6%+15.8%
Q1 2020-4.8%-2.0%-6.2%
Q4 2019+1.6%+1.0%+4.2%
Q3 2019+3.8%-3.5%-5.6%
Q2 2019+7.8%+5.5%+6.1%
Q1 2019+6.7%+9.2%+5.7%
Q4 2018-2.3%+0.3%-2.9%
Q3 2018+1.9%+5.0%+13.2%
Q2 2018-4.3%-5.1%-6.6%
Q1 2018+2.5%-2.9%+4.7%
Q4 2017-2.4%-2.2%+10.9%
Q3 2017-11.4%-12.0%-12.1%
Q2 2017+3.9%+5.9%+13.2%
Q1 2017+6.0%+6.8%+9.9%
Q4 2016+3.6%+3.1%+12.9%
Q3 2016+5.1%+4.5%+1.9%
Q2 2016-9.2%
Q1 2016-3.7%
Q4 2015-1.0%
Q3 2015-5.4%
Q2 2015+1.9%
Q1 2015+0.4%
Q4 2014+7.1%
Q3 2014+3.7%
Q2 2014-3.1%
Q1 2014-4.3%
Q4 2013+1.8%
Q3 2013-0.0%
Q2 2013-4.6%
Q1 2013-5.1%
Q4 2012-0.6%
Q3 2012+2.7%
Q2 2012-1.2%
Q1 2012+2.4%
Q4 2011-1.0%
Q3 2011-0.5%
Q2 2011+2.9%
Q1 2011+0.5%
Q4 2010-0.5%
Q3 2010-0.7%
Q2 2010+1.0%
Q1 2009-1.7%
Q1 2010+1.2%
Q4 2009-0.6%
Q2 2009-0.6%
Q4 2007-0.6%
Q3 2008-0.5%
Q3 2009-0.5%
Q4 2008-0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro